Cutaneous immune‐related adverse events from immune checkpoint inhibitor therapy: Moving beyond “maculopapular rash”
Immunological Reviews · 2023
DOI: 10.1111/imr.13257 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunological Reviews, 2023. Verfasst von Blair S Allais und 4 weiteren Autor:innen. Beteiligte Einrichtung: Inova Schar Cancer Institute, Melanoma and Skin Cancer Center, Fairfax, Virginia, USA. Hauptthemen laut MEDLINE: Exanthema, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
Uncoupling toxicity from therapeutic effect lies at the foundation of the current state of the field of cutaneous immune‐related adverse events to immune checkpoint inhibitor therapy. This will be achieved through understanding the drivers of toxicity, tumor response, and resistance via large, well‐powered population‐level studies, institutional cohort data, and cellular‐level data. Increasing diagnostic specificity through the application of consensus disease definitions has the power to improve clinical care and each approach to research. Cutaneous immune‐related adverse events are associated with increased survival, and their treatment must invoke the maintenance of a delicate balance between immunosuppression, anti‐tumor effect of immune checkpoint inhibitor therapy, and quality of life. The multidisciplinary care of cancer patients with adverse events is critical to optimizing clinical and translational research outcomes and, as such, dermatologists are vital to moving the study of cutaneous adverse events forward.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Inova Schar Cancer Institute, Melanoma and Skin Cancer Center, Fairfax, Virginia, USA.
- The Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Harvard-MIT Health Sciences and Technology Program, Harvard Medical School, Boston, Massachusetts, USA.
- Harvard Medical School, Boston, Massachusetts, USA.
- Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA.
ORCID-Profile: Nicole R LeBoeuf
Zitieren
APA
Allais, B. S., Fay, C. J., Kim, D. Y., Semenov, Y. R., & LeBoeuf, N. R. (2023). Cutaneous immune‐related adverse events from immune checkpoint inhibitor therapy: Moving beyond “maculopapular rash”. Immunological Reviews. https://doi.org/10.1111/imr.13257
Vancouver
Allais BS, Fay CJ, Kim DY, Semenov YR, LeBoeuf NR. Cutaneous immune‐related adverse events from immune checkpoint inhibitor therapy: Moving beyond “maculopapular rash”. Immunological Reviews. 2023. doi:10.1111/imr.13257
BibTeX
@article{Allais2023,
author = {Allais, Blair S and Fay, Christopher J and Kim, Daniel Y and Semenov, Yevgeniy R and LeBoeuf, Nicole R},
title = {Cutaneous immune‐related adverse events from immune checkpoint inhibitor therapy: Moving beyond “maculopapular rash”},
journal = {Immunological Reviews},
year = {2023},
doi = {10.1111/imr.13257}
}
EUVIMED